Important nuance: the favorable glycemic signal in this trial sits on a secondary measure (HOMA-IR), while the pre-specified primary insulin-sensitivity endpoint was null. Baseline ISI 8.9 x 10^-4.
Important nuance: the favorable glycemic signal in this trial sits on a secondary measure (HOMA-IR), while the pre-specified primary insulin-sensitivity endpoint was null. Baseline ISI 8.9 x 10^-4.